BioWorld Asia

April 11, 2007

View Archived Issues

Affimed Raises $33.5M For TandAbs In Oncology

Affimed Therapeutics AG raised €25 million (US$33.5 million) in a Series B round to fund its two lead programs, in non-Hodgkins lymphoma (NHL) and Hodgkin's disease. Each is in preclinical development at present. (BioWorld International) Read More

Stem Cells Sciences Raises $9.9M With New ASX Listing

Read More

Innate Immunity, New Combo Of Antibiotics Fight Resistance

Read More

Patients' Group Voices Anger At Advanced Therapies Tactic

Read More

Atlantic Closes First Deal, Licensing GI Compound

Read More

Nokad Obtains Its First Functional KOs in Rats

Read More

Other News To Note

Read More